• (PLX AI) – CureVac Q1 revenue EUR 24.4 million vs. estimate EUR 9.5 million.
  • • Q1 EBIT EUR -15.3 million vs. estimate EUR -98 million
  • • Partners with myNEO to identify novel antigen targets for mRNA-based cancer vaccine development
  • • The partnership combines CureVac’s mRNA technology with myNEO’s platform for the discovery and selection of tumor antigens predicted to elicit strong immune responses
  • • Together with myNEO, CureVac aims to identify specific antigens for the development of novel mRNA cancer vaccines

Quelle: PLX AI